Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia Microelectrodes (“ME”) are implanted in the brain and connected to a pulse generator that delivers electrical

During aging, the central nervous system (“CNS”) becomes more inflammatory, leading to activation of microglia (“CNS immune cells”), tissue damage, dysfunction, and senescence The article reviews microglial pathways, including the NLRP3 inflammasome pathway, which are promising drug targets for

Mr. Glover will participate in a live interview on Benzinga All Access on April 18, 2023, to discuss the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, for renal disease, and Inflammasome ASC Inhibitor IC 100 for CNS and non-CNS inflammatory diseases WESTON,

Mr. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS and other inflammatory diseases WESTON, Fla., April 11, 2023 (GLOBE NEWSWIRE) -- ZyVersa

Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development Expression of ASC correlates with Aβ and p-tau in postmortem AD, indicating increased deposition is

Key Highlights: Closed business combination with Larkspur Health Acquisition Corp. in December 2022 and began trading on Nasdaq Global Market under the ticker symbol “ZVSA” Planning underway with nephrologists for an investigator-initiated clinical trial in focal segmental glomerulosclerosis

WESTON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA , or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet medical needs, today announced the grant

Cholesterol Efflux Mediator VAR 200 is a phase 2a-ready drug in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to progression of kidney disease WESTON, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc.

CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for multiple CNS and other inflammatory diseases WESTON, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- ZyVersa

CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 which has potential to treat multiple CNS and other inflammatory diseases WESTON, Fla., Feb.